NF1 and neurofibromatosis type 1: In pursuit of new cognitive therapies for NF1 patients, one study found that the HMG CoA reductase inhibitor lovastatin that inhibits RAS activity, can decrease RAS activity in the brain and rescue spatial learning and attention impairments in Nf1+/− mice (Li et al., 2005).